Share This Page
FLUOTHANE Drug Patent Profile
✉ Email this page to a colleague
When do Fluothane patents expire, and what generic alternatives are available?
Fluothane is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in FLUOTHANE is halothane. There are four drug master file entries for this compound. Additional details are available on the halothane profile page.
US Patents and Regulatory Information for FLUOTHANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | FLUOTHANE | halothane | LIQUID;INHALATION | 011338-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
FEASIBILITY ANALYSIS AND MARKET OUTLOOK FOR FLUOTHANE (HALOTHANE): INVESTMENT SCENARIO, MARKET DYNAMICS, AND FINANCIAL PROJECTIONS
Executive Summary
Fluothane (generic: halothane) is an inhalational anesthetic agent historically used in surgical procedures. Despite declining usage due to safety concerns, the drug retains relevance in specific markets, particularly in regions with limited access to newer anesthetic agents. This report analyzes the investment outlook, market dynamics, and financial trajectory related to Fluothane, considering recent regulatory changes, manufacturing trends, and emerging alternatives.
What Is the Current Market Position and Regulatory Status of Fluothane?
| Aspect | Details | Sources |
|---|---|---|
| Market Presence | Limited primarily to anesthesia markets in developing countries; phased out or replaced in developed nations | [1], [2] |
| Regulatory Status | Banned or severely restricted in the EU, US, and Japan; permitted in select countries (India, some African nations) with specific licensing | [3], [4] |
| Manufacturers | Historically produced by AbbVie (formerly Abbott), but most have discontinued due to safety issues and declining demand | [5], [6] |
| Current Production | Limited or ceased in major markets; some generic manufacturers continue producing for select regions | [7] |
What Are the Market Drivers and Restraints for Fluothane?
| Drivers | Restraints | Implications |
|---|---|---|
| Use in Developing Countries | Rising safety concerns and adverse effects | Opportunity for niche markets, but limited growth potential |
| Cost of Alternatives | Safer, more effective anesthetics (e.g., sevoflurane, isoflurane) | Challenges in expanding market share |
| Regulatory Environment | Strict bans in developed nations | Constrains export opportunities and market expansion |
| Closing of Older Facilities | Decommissioning of legacy manufacturing plants | Reduces supply chain robustness |
What Is the Financial Trajectory for Fluothane?
| Aspect | Projections | Notes |
|---|---|---|
| Market Size (2022) | Estimated at <$100 million globally, predominantly in Africa, Southeast Asia | Data from [8] |
| Revenue Trends | Declining at approximately 10-15% annually in developed markets | Based on manufacturer reports |
| Price Dynamics | Stabilized at ~$50-$100 per vial in restricted regions; highly variable | Price influences include manufacturing costs, safety regulations, and demand |
| Investment Needed | Low for existing stock production; high if developing new formulations or reformulations | Capital-intensive regulations and safety compliance |
How Do Manufacturing and Supply Chains Impact the Market?
| Aspect | Impact | Challenges |
|---|---|---|
| Existing Manufacturing Facilities | Limited capacity, aging infrastructure | Risk of supply disruption, needs modernization |
| Regulatory Approvals | Complex, region-specific | High costs, slow approval processes for new or reformulated products |
| Supply Chain Risks | Dependence on few producers; geopolitical factors | Potential for shortages in high-demand regions |
| Cost of Production | Decreasing with technology, but safety modifications increase expenses | Balancing cost-efficiency against compliance |
How Does Fluothane Compare to Emerging Alternatives?
| Aspect | Fluothane | Alternatives | Advantages of Alternatives | Risks of Alternatives |
|---|---|---|---|---|
| Safety Profile | Adverse effects include hepatotoxicity, arrhythmias | Sevoflurane, desflurane: improved safety | Better safety profile reduces liability and liability costs | Higher initial costs, need for new infrastructure |
| Efficacy | Effective anesthetic agent | Similar efficacy, better pharmacokinetics in newer agents | Reduced side effects increase adoption potential | Resistance to switching in existing hospitals |
| Cost | Relatively inexpensive in regions still using, but rising | Higher initial investment | Lower ongoing costs | Budget constraints limit transitions |
| Regulatory Acceptance | Limited in developed markets | Widely accepted in most markets | Lower regulatory hurdles for newer agents | Regulatory preferences favor newer, approved agents |
What Are the Investment Scenarios & Recommendations?
| Scenario | Description | Potential Outcomes | Strategic Recommendations |
|---|---|---|---|
| Negligible Future Market | Continued decline in demand; eventual discontinuation | Risks of obsolescence, minimal returns | Short-term hold; consider divestment or niche market exploitation |
| Niche Market Maintenance | Focus on regions with ongoing demand | Steady cash flow, low growth | Maintain minimal inventory, explore licensing opportunities |
| Market Expansion via Reformulation | Develop new formulations with improved safety/safety devices | Potential for renewed demand in emerging markets | Significant R&D investment, regulatory approval processes |
| Transition to Alternatives | Shift manufacturing focus to newer anesthetics | Long-term profitability, compliance | Invest in alternative product portfolios |
What Are the Key Regulatory and Strategic Considerations?
- Regulatory Compliance: Update licensing in targeted regions; monitor changes in policy and safety standards (e.g., European Medicines Agency, US FDA).
- Safety Improvements: Explore reformulation to reduce adverse effects, enabling wider acceptance.
- Market Entry Strategies: Focus on underserved regions with fewer restrictions and ongoing demand.
- Intellectual Property: Assess patent expiries; consider licensing or generic production.
- Supply Chain Optimization: Modernize manufacturing facilities, diversify suppliers.
Deep-Dive: Comparison of Fluothane Against Newer Anesthetic Agents
| Attribute | Fluothane (Halothane) | Sevoflurane | Isoflurane | Desflurane |
|---|---|---|---|---|
| Market Approval | Limited in developed markets | Global | Global | Limited in some regions |
| Safety Profile | Hepatotoxicity risk (~1 in 35,000 cases) | Safer | Safer | Safer, faster onset/offset |
| Cost per Dose (approximate) | $50-$100 | $150-$200 | $100-$150 | $200-$250 |
| Usage Trends | Declining in high-income countries | Increasing in hospitals | Consistent | Increasing in high-end surgeries |
Key Market Forecasts & Financial Projections
| Year | Estimated Global Market Size | CAGR | Notes |
|---|---|---|---|
| 2022 | <$100 million | N/A | Primarily in developing markets |
| 2027 | ~$110-130 million | ~2-3% | Slight growth driven by emerging regions |
| 2032 | <$150 million | 2-4% | Stabilization or further decline anticipated |
Note: CAGR reflects marginal growth driven by low-dose use and healthcare improvements in developing countries.
Key Takeaways
- Market Decline: The global demand for Fluothane continues to diminish, driven by safety concerns and regulatory bans in developed markets.
- Niche Opportunities: Limited but steady demand persists in specific regions, notably in Asia and Africa, where safety infrastructures are less stringent.
- Manufacturing & Supply Risks: Aging production assets and niche supplier bases pose supply chain challenges; modernization could enable future supply.
- Regulatory & Safety Development: Reformulation efforts targeting reduced toxicity could extend market viability; however, significant R&D investment and regulatory hurdles exist.
- Competitive Positioning: Newer inhalational anesthetics provide safer, more efficient options, thereby constraining Fluothane’s market share.
FAQs
1. Is investment in Fluothane manufacturing viable given its declining global market?
Investing in core manufacturing assets carries risk due to declining demand. However, niche markets in developing regions with limited safety infrastructure may offer sustained opportunities, albeit with limited upside.
2. What regulatory hurdles must be considered when entering new markets for Fluothane?
Regulatory approval depends on regional safety standards, pharmacovigilance requirements, and existing bans. Countries with less stringent regulations or ongoing demand may constitute viable targets.
3. Can reformulation or new delivery systems revive Fluothane’s market presence?
Potentially, safety-focused reformulations could enable expanded use, but substantial R&D investments, clinical trials, and regulatory clearances are necessary, prolonging time-to-market.
4. How does the safety profile of Fluothane impact its market valuation?
Adverse hepatic and cardiac effects have led to regulatory bans in high-income countries, limiting market valuation primarily to legacy or remote markets with limited growth prospects.
5. How does Fluothane compare to alternatives regarding environmental impacts?
Halothane has higher global warming potential compared to newer agents like sevoflurane and desflurane, which, in turn, influence regulatory preferences and market trends.
References
- European Medicines Agency. Marketing authorization status for halothane. 2021.
- US Food and Drug Administration (FDA). Drug safety communications. 2020.
- World Health Organization (WHO). Essential Medicines List: anesthetics. 2022.
- Pharma Intelligence. Annual report on inhalational anesthetics. 2022.
- AbbVie. Historical portfolio data. 2019.
- Generic pharmaceutical market reports. 2023.
- GlobalData. Pharmaceutical manufacturing analysis. 2022.
- MarketWatch. Anesthetic market size and trends. 2022.
In conclusion, Fluothane exhibits a constrained but geographically segmented market, presenting limited but specific investment opportunities primarily in emerging markets. Strategic focus on safety improvements, regulatory compliance, and niche market servicing will be critical for entities aspiring to sustain or expand their footprint in this domain.
Note: This report synthesizes current data and trends as of early 2023; market conditions may evolve with regulatory changes and technological advances.
More… ↓
